Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants.

Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release (2012) 0.95

Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses (2013) 0.79

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29

Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity (2005) 2.16

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06

Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res (2004) 2.02

Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69

Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol (2006) 1.67

Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55

Vaginal drug delivery systems for HIV prevention. AAPS J (2009) 1.51

Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology (2004) 1.38

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37

Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol (2004) 1.37

Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34

CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis (2003) 1.29

RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol (2010) 1.27

Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology (2003) 1.23

Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN. J Virol (2007) 1.23

Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med (2011) 1.15

PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology (2010) 1.15

Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One (2009) 1.09

Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother (2001) 1.07

RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol (2011) 1.04

Contraceptive vaginal rings: a review. Contraception (2010) 1.04

Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04

The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice. J Virol (2005) 1.04

Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res (2008) 1.04

Therapeutic and diagnostic applications of nanoparticles. Curr Drug Targets (2011) 1.00

Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv (2010) 1.00

Progress in RNAi-based antiviral therapeutics. Methods Mol Biol (2011) 0.98

Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci (2011) 0.98

HIV type 1 infection in women: increased transcription of HIV type 1 in ectocervical tissue explants. J Infect Dis (2009) 0.97

Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.95

Caveats associated with the use of human cervical tissue for HIV and microbicide research. AIDS (2010) 0.95

Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS (2002) 0.94

Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol (2009) 0.94

Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther (2011) 0.94

HIV-1 in semen: determination of proviral and viral titres compared to blood, and quantification of semen leukocyte populations. J Med Virol (1999) 0.92

Isolation of human immunodeficiency virus type 1 from semen and vaginal fluids. Methods Mol Biol (2005) 0.92

Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials (2010) 0.92

Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res (2011) 0.91

Nanoparticle-induced apoptosis propagates through hydrogen-peroxide-mediated bystander killing: insights from a human intestinal epithelium in vitro model. ACS Nano (2010) 0.90

Innate factors in human breast milk inhibit cell-free HIV-1 but not cell-associated HIV-1 infection of CD4+ cells. J Acquir Immune Defic Syndr (2009) 0.90

Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm (2008) 0.89

Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides (2006) 0.87

A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J Pharm Sci Technol (2011) 0.85

Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics. J Postgrad Med (2006) 0.85

Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther (2006) 0.85

Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands. Virology (2001) 0.82

Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin Vaccine Immunol (2008) 0.82

Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J Immunother (2010) 0.81

Multivalent catanionic GalCer analogs derived from first generation dendrimeric phosphonic acids. Bioorg Med Chem (2009) 0.79